Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)

被引：0
|
作者：
Weinberg, B. [1 ]
He, A. [1 ]
Tan, B. [2 ]
Turk, A. [3 ]
Noel, M. [1 ]
Marshall, J. [1 ]
Sung, M. [4 ]
Wang, H. [1 ]
Ferguson, C. [1 ]
Swanson, N. [1 ]
Pedersen, K. [2 ]
机构：
[1] Georgetown Univ, Ruesch Ctr Cure Gastrointestinal Canc, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Indiana Univ Sch Med, Dept Hematol Oncol, Indianapolis, IN USA
[4] Tisch Canc Inst Mt Sinai, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.287
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-231
引用
收藏
页码：S97 / S98
页数：2
相关论文
共 50 条
  • [41] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy.
    Pelzer, Uwe
    Blanc, Jean-Frederic
    Melisi, Davide
    Cubillo, Antonio
    Von Hoff, Daniel D.
    Wang-Gillam, Andrea
    Chen, Li-Tzong
    Siveke, Jens T.
    Wan, Yin
    Solem, Caitlyn T.
    Botteman, Marc
    Yang, Yoojung
    de Jong, Floris
    Hubner, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Siveke, Jens T.
    Hubner, Richard
    Macarulla, Teresa Mercade
    Wang-Gillam, Andrea
    Dean, Andrew Peter
    Blanc, Jean-Frederic
    Cunningham, David
    Mirakhur, Beloo
    Belanger, Bruce
    de Jong, Floris A.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [43] Randomized phase II study of nalicap (nalIRI/capecitabine) compared to NAPOLI ( nal-IRI/5F-U/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress
    Oh, Do-Youn
    Kim, Jin Won
    Lee, Myung Ah
    Kim, Ilhwan
    Lee, Choong-kun
    Seol, Young Mi
    Yoo, Changhoon
    Oh, Sang Cheul
    Bae, Woo Kyun
    Chon, Hongjae
    Choi, In Sil
    Yoon, Jeesun
    Park, Joon Oh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [44] Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPOLI-1 trial
    Chen, Li-Tzong
    Wang-Gillam, Andrea
    Yanshen, Shan
    Macarulla, Teresa
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Pipas, J. Marc
    Belanger, Bruce
    de Jong, Floris
    Mamlouk, Khalid
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [45] A RANDOMIZED PHASE II STUDY OF BIWEEKLY IRINOTECAN VERSUS IRINOTECAN PLUS 5-FLUOROURACIL/LEUCOVORIN AS A SALVAGE CHEMOTHERAPY IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED GASTRIC CANCER
    Sym, S.
    Park, Y.
    Park, S.
    Park, J.
    Cho, E.
    Lee, W.
    Chung, M.
    Shin, D.
    Lee, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 25 - 25
  • [46] Phase II study of irinotecan and fluorouracil/leucovorin (FOLFIRI) in patients with primary advanced gastric cancer: Preliminary results
    Cordio, S.
    Rosati, G.
    Camaghi, C.
    Mattina, M.
    Lavenia, G.
    Sambataro, D.
    Latteri, F.
    Salice, P.
    Sergi, C.
    Amadio, P.
    Parra, H. Soto
    ANNALS OF ONCOLOGY, 2005, 16 : 49 - 49
  • [47] Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone
    Hubner, R. A.
    Chen, L-T.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Lee, K-H.
    Cunningham, D.
    Siveke, J. T.
    Braiteh, F. S.
    de Jong, F. A.
    Belanger, B.
    Walls, R.
    Mody, P. D.
    von Hoff, D. D.
    Wang-Gillam, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Results of a multi-center phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer
    Schuette, K.
    Moehler, M.
    Kettner, E.
    Hegewisch-Becker, S.
    Goekkurt, E.
    Al-Batran, S.
    Steffens, C.
    Ehninger, G.
    Stoehlmacher, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 395 - 395
  • [49] Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±-5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.
    Macarulla, Teresa Mercade
    Hubner, Richard
    Blanc, Jean-Frederic
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew Peter
    Yanshen, Shan
    Jameson, Gayle S.
    Lee, Kyung-Hun
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Braiteh, Fadi S.
    Cunningham, David
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    Mamlouk, Khalid Kevin
    de Jong, Floris A.
    Siveke, Jens T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [50] A phase II study of leucovorin (LV)-modulated continuous infusion (CI) fluorouracil (FU) plus irinotecan (IRI) alternating with LV-modulated CIFU plus oxaliplatin (OXA) in advanced colorectal cancer (CRC): high activity and low toxicity
    Aschele, C
    Lonardi, S
    Sartor, L
    Perin, A
    Artioli, G
    Monfardini, S
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 438 - 438
12345